论文部分内容阅读
背景和目的:有说服力的证据表明血管紧张素转换酶(AEC)抑制剂和血管紧张素Ⅱ受体阻滞剂在用于肾小球疾病的白蛋白尿时,具有一种特殊的与血压无关的作用。因为肾小球疾病的发展并不一定受此类药物的制止,故需要探索其它药物对。肾脏的潜在保护作用。近期动物研究证明,非降压剂量的莫索尼定(M0xonidine,是一种交感神经麻痹剂),也能以与血压无关的方式减少白蛋白尿和肾小球硬化的发生。
Background and Objective: There is compelling evidence that angiotensin-converting enzyme (AEC) inhibitors and angiotensin II receptor blockers have a specific association with blood pressure when used in albuminuria for glomerular diseases Irrelevant effect. Because the development of glomerular disease is not necessarily stopped by these drugs, it is necessary to explore other drug pairs. Kidney potential protective effect. Recent animal studies have shown that non-depressing doses of moxonidine (a sympathomimetic agent) can also reduce albuminuria and glomerulosclerosis in a manner unrelated to blood pressure.